DEVELOPPEMENT PHARMA GESTION SERVICES : revenue, balance sheet and financial ratios

DEVELOPPEMENT PHARMA GESTION SERVICES is a French company founded 37 years ago, specialized in the sector Conseil pour les affaires et autres conseils de gestion. Based in SIN-LE-NOBLE (59450), this company of category PME shows in 2019 a revenue of 808 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-04-18

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - DEVELOPPEMENT PHARMA GESTION SERVICES (SIREN 345283790)
Indicator 2023 2022 2019 2018 2017 2016 2015
Revenue N/C N/C 807 687 € N/C N/C 1 124 128 € 1 716 605 €
Net income 637 467 € 607 776 € 435 010 € 569 219 € 692 542 € 682 866 € 1 297 758 €
EBITDA N/C N/C 376 835 € N/C N/C 623 745 € 1 249 336 €
Net margin N/C N/C 53.9% N/C N/C 60.7% 75.6%

Revenue and income statement

In 2023, DEVELOPPEMENT PHARMA GESTION SERVICES generates positive net income of 637 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2015-2023: 1.3 M€ -> 637 k€.

Net income (2023) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

637 467 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 48%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 40%. The balance between equity and debt is satisfactory.

Debt ratio (2023) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

48.171%

Financial autonomy (2023) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

39.676%

Asset age ratio (2023) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

1.1%

Solvency indicators evolution
DEVELOPPEMENT PHARMA GESTION SERVICES

Sector positioning

Debt ratio
48.17 2023
2019
2022
2023
Q1: 0.0
Med: 4.57
Q3: 46.63
Average +24 pts over 3 years

In 2023, the debt ratio of DEVELOPPEMENT PHARMA GEST... (48.17) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
39.68% 2023
2019
2022
2023
Q1: 4.34%
Med: 38.51%
Q3: 74.89%
Good

In 2023, the financial autonomy of DEVELOPPEMENT PHARMA GEST... (39.7%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.

Repayment capacity
0.12 years 2019
2019
Q1: 0.0 years
Med: 0.0 years
Q3: 0.68 years
Average

In 2019, the repayment capacity of DEVELOPPEMENT PHARMA GEST... (0.12) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 251.29. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2023) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

251.29

Liquidity indicators evolution
DEVELOPPEMENT PHARMA GESTION SERVICES

Sector positioning

Liquidity ratio
251.29 2023
2019
2022
2023
Q1: 139.84
Med: 306.31
Q3: 899.92
Average +9 pts over 3 years

In 2023, the liquidity ratio of DEVELOPPEMENT PHARMA GEST... (251.29) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.

Interest coverage
0.0x 2019
2019
Q1: 0.0x
Med: 0.0x
Q3: 0.24x
Average

In 2019, the interest coverage of DEVELOPPEMENT PHARMA GEST... (0.0x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.

Operating WCR (2023) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2023) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

0 j

Supplier credit (2023) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

0 j

Inventory turnover (2023) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
DEVELOPPEMENT PHARMA GESTION SERVICES

Positioning of DEVELOPPEMENT PHARMA GESTION SERVICES in its sector

Comparison with sector Conseil pour les affaires et autres conseils de gestion

Valuation estimate

Based on 66 transactions of similar company sales in 2023, the value of DEVELOPPEMENT PHARMA GESTION SERVICES is estimated at 4 425 730 € (range 2 187 266€ - 11 428 154€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.

Estimated enterprise value 2023
66 tx
2187k€ 4425k€ 11428k€
4 425 730 € Range: 2 187 266€ - 11 428 154€
NAF 5 année 2023

Valuation method used

Net Income Multiple
637 467 € × 6.9x = 4 425 730 €
Range: 2 187 266€ - 11 428 154€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 66 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Conseil pour les affaires et autres conseils de gestion)

Compare DEVELOPPEMENT PHARMA GESTION SERVICES with other companies in the same sector:

Voir toutes les statistiques du secteur Conseil pour les affaires et autres conseils de gestion

Frequently asked questions about DEVELOPPEMENT PHARMA GESTION SERVICES

What is the revenue of DEVELOPPEMENT PHARMA GESTION SERVICES ?

The revenue of DEVELOPPEMENT PHARMA GESTION SERVICES in 2019 is 808 k€.

Is DEVELOPPEMENT PHARMA GESTION SERVICES profitable?

Yes, DEVELOPPEMENT PHARMA GESTION SERVICES generated a net profit of 637 k€ in 2023.

Where is the headquarters of DEVELOPPEMENT PHARMA GESTION SERVICES ?

The headquarters of DEVELOPPEMENT PHARMA GESTION SERVICES is located in SIN-LE-NOBLE (59450), in the department Nord.

Where to find the tax return of DEVELOPPEMENT PHARMA GESTION SERVICES ?

The tax return of DEVELOPPEMENT PHARMA GESTION SERVICES is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does DEVELOPPEMENT PHARMA GESTION SERVICES operate?

DEVELOPPEMENT PHARMA GESTION SERVICES operates in the sector Conseil pour les affaires et autres conseils de gestion (NAF code 70.22Z). See the 'Sector positioning' section above to compare the company with its competitors.